FDA
-
-
-
-
-
-
-
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor and PPMD to host webinar on phase 3 trial results
-
-
-
-
-
-
-
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor schedules FDA meeting on Deramiocel regulatory path
-
325,591 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

